Cerebral is a clinical-stage pharmaceutical company developing innovative treatments for uncontrolled neurological diseases.
Cerebral is dedicated to improving the lives of patients living with severe refractory epilepsy and other uncontrolled neurological diseases.
Cerebral was founded in 2019 by Kyle Robertson and Ho Anh. The company is headquartered in San Francisco, California.
Cerebral offers counseling, therapy and medication delivery and management online for mental and behavioral health conditions such as depression, anxiety, serious mental illnesses, substance use disorder and nutrition.
Cerebral is currently in-network with major health plans such as Aetna, Blue Cross Blue Shield, Cigna, Magellan and Medicare, covering more than 80 million lives, and continuing to grow. The company also is partnering with a growing number of employers.
Cerebral has more than 2,000 clinicians practicing across all 50 states, which enables the company to dramatically cut wait times compared to traditional mental health providers. The company has provided care to more than 200,000 patients.
Cerebral is backed by SoftBank Vision Fund 2, WestCap, RA Capital Management, Access Industries, Perceptive Advisors, Vivo Capital, Silver Lake Waterman, Prysm Capital, Artis Ventures, and others. The company raised $300M in Series C round on Dec 08, 2021. This brings Cerebral's total funding to $462M to date. The latest round pushed the company's valuation to $4.8B, which is four times larger than their previous $1.2B gained from a Series B raised in Jun 2021.